Septic shock has a 40% mortality rate in many patients. Methylene blue has been shown in small non-controlled case series to have a benefit. Join host, Geoff Wall, as he reviews a randomized controlled study from Mexico on this novel strategy.
 
The GameChanger
Methylene blue is a specific inhibitor of the inducible nitric oxide synthase for indirect pressor effects. Despite confounders, this small study may be a good start for a larger randomized controlled study for methylene blue as early adjunct care in patients with septic shock.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Ibarra-Estrada M, Kattan E, Aguilera-González P, et al. Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care. 2023 Mar 13;27(1):110. doi: 10.1186/s13054-023-04397-7. PMID: 36915146; PMCID: PMC10010212.
 
Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)

 

CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the potential physiologic mechanism of benefit for methylene blue in septic shock
2. Discuss the Ibarra-Estrada et al study limitations

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-212-H01-P
Initial release date: 6/5/2023
Expiration date: 6/5/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram